Protooncogenes are Dominant: 1 mutant allele needed (ret, ras, abl, myc,
Antioncogenes are Recessive: both alleles must be mutated (Rb, p53, APC,
WT-1, BRCA, p16, NF-1)
Apoptosis genes: bcl-2 (inhibits), bax, bad (promote)
Gene amplification: Double minutes or HSR. In N-myc (neuroblastoma) or
c-erb B2/her-2-neu (breast) indicate poor prognosis.
abl - non-receptor tyrosine kinase
APC - signal transduction
bcl-2 - located in outer mitochondrial membrane, er, and nuclear membrane;
believed to prevent exit of cytochrome c from mitochondria.
BRCA - DNA repair; rare in sporadic breast cancer. 80% of familial breast
ca. though familial is 5-10% of total breast ca.
Both increase risk of ovarian ca; BRCA1 increases risk of prostate
and colon; BRCA2 increases risk of male breast ca.
NF-1 - signals ras
ras - GTP binding protein, single most common abnormal oncogene in human
tumors (10-20% all tumors), protein binds GTPase activating protein (GAP); mutant
ras leaves GAP in permanent "on" position.
Rb - cell cycle regulator; active underphosphorylated form stops G1 -
S by binding/sequestering E2F transcription factors; hyperphosphorylated is
Four genes regulate phosphorylation of Rb: Rb, cyclin D, cdk4, p16(aka ink4)
which inhibits cdk4.
E7 protein of HPV binds and inactivates Rb.
p53 - cell cycle regulator; single most common target for genetic alterations
in human tumors. Radiation and chemo mediate their effects through p53. E6 protein
of HPV inactivates p53.
actions of p53: growth arrest without damage
· induces cdk inhibitor p21
· if repair successful, induces mdm2, which downregulates
· if repair unsuccessful, induces apoptosis genes
Tumors and Cell Cycle:
Oncogene mutations allow cells to go into G1-S more easily than normal; Not
usually associated with a shortened cell cycle time.
Cyclins: control transition from G1 - S; Cyclin D (mantle cell t(11,14)(q13q32),
cdks: cdks 2 binds Cyclin E; 4 & 6 bind D